The EPS beat and revenue growth are overshadowed by the revenue miss vs consensus and widening losses. The key catalyst is the DECLARATION top-line data in Q3 2026, monitor for enrollment completion and event accumulation updates. The ATM raise and cash runway suggest no near-term financing urgency, but the 158% share count dilution over the past year is a structural overhang.
IVVD drugs
IVVD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 14 $1.16entry
- T+1 · 6mo ago +4.31%α +5.54% · $1.21
- T+5 · 6mo ago −4.31%α −3.59% · $1.11
- T+20 · 5mo ago −33.62%α −32.76% · $0.7700
- T+60 · 3mo ago −41.97%α −45.56% · $0.6731
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Invivyd reported Q1 2026 PEMGARDA revenue of $13.7M (+22% YoY), beating consensus estimates on both revenue ($13.7M vs $18.1M expected) and EPS (-$0.04 vs -$0.08 expected). The company highlighted continued in vitro neutralizing activity against the BA.3.2.2 variant, IDMC recommendation to reduce post-dose monitoring time for VYD2311, and a strong cash position of $184.2M providing runway through the DECLARATION data readout in Q3 2026. However, net loss widened to $41.4M from $16.3M a year ago due to increased R&D spending on the DECLARATION trial, and the company raised ~$20M via ATM in April.
Key Financial Metrics
Key Facts
- Q1 2026 PEMGARDA net product revenue $13.7M, up 22% from $11.3M in Q1 2025
- EPS -$0.04 beat consensus of -$0.08 (50% beat)
- Revenue $13.7M missed consensus of $18.1M (24% miss)
- Net loss widened to $41.4M from $16.3M YoY, driven by $30.7M R&D (vs $10.6M)
- Cash and equivalents $184.2M as of March 31, 2026; additional ~$20M raised via ATM in April 2026
- IDMC recommended reduction of VYD2311 post-dose monitoring from 2 hours to 30 minutes
- DECLARATION trial upsized by ~500 subjects; top-line data expected Q3 2026 (shifted from mid-2026)
- Measles mAb candidate VMS063 advancing toward IND readiness in late 2026
- Weighted-average shares outstanding 309.7M (basic/diluted), up 158% YoY from 119.9M
Financial Impact
Revenue beat consensus by 24% on a dollar basis ($13.7M vs $18.1M), but EPS beat was on a small absolute base. Net loss widened significantly. Cash burn rate increased.
Risk Factors
- Revenue miss vs consensus of $18.1M despite 22% YoY growth, top-line expectations may have been too high
- Net loss more than doubled to $41.4M with R&D spending tripling; cash burn rate is accelerating
- DECLARATION trial upsized by ~500 subjects, pushing data readout to Q3 2026, adds execution risk and delays catalyst
- 158% YoY dilution in weighted-average shares outstanding pressures per-share metrics
- PEMGARDA EUA is contingent on variant susceptibility; future variants could reduce its effectiveness
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294770 |
Track record
19 reports on IVVD
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
- Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
- Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
- Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
- Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
- Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
- Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers